688
Participants
Start Date
April 20, 2022
Primary Completion Date
June 27, 2025
Study Completion Date
June 27, 2025
Palbociclib
Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC
Endocrine therapy
Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC
Nagoya University Hospital, Nagoya
National Hospital Organization Shikoku Cancer Center, Matsuyama
Japan Community Health care Organization Kurume General Hospital, Kurume
Hokkaido Cancer Center, Sapporo
Ishikawa Prefectural Central Hospital, Kanazawa
Kitasato University Hospital, Sagamihara
Tohoku University Hospital, Sendai
Kaizuka City Hospital, Kaizuka
Osaka International Cancer Institute, Osaka
Osaka University Hospital, Suita
Saitama Prefectural Cancer Center, Kita-adachi-gun
Seirei Hamamatsu General Hospital, Hamamatsu
Jichi Medical University Hospital, Shimotsuke
Gifu University Hospital, Gifu
Hiroshima University Hospital, Hiroshima
Tokai University Hospital, Kanagawa
Aichi Cancer Center, Nagoya
National Hospital Organization Osaka National Hospital, Osaka
Shizuoka Prefectural Hospital Organization, Shizuoka
Showa University Hospital, Tokyo
Lead Sponsor
Pfizer
INDUSTRY